TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22381024

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate (LC) diet
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Reduced glycemic load (RGL) diet
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard portion-controlled (PC) diet
Number of subjects: 102
Study: 21164547

Group type: EXPERIMENTAL
Intervention: Resistance training (n = 8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (n = 8)
Number of subjects: 16
Study: 16716604

Group type: EXPERIMENTAL
Intervention: Glucagon (0.5 mg IV bolus)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucagon (0.5 mg IV bolus) repeated 7 hours later
Number of subjects: 0
Study: 15618341

Group type: EXPERIMENTAL
Intervention: Static stretching of quadriceps and hamstring muscles (three 30 second stretches)
Number of subjects: 20
Study: 12002498

Group type: COMPARATOR
Intervention: Uncoated stainless-steel screws
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Partly coated with HA screws
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Fully coated HA screws
Number of subjects: 23
Study: 10213463

Group type: EXPERIMENTAL
Intervention: IFN-alpha2 treatment for 8 weeks
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Responders (14 patients)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Nonresponders (13 patients)
Number of subjects: 27
Study: 7799019

Group type: EXPERIMENTAL
Intervention: R2 resection with extended lymphadenectomy
Number of subjects: 473

Group type: COMPARATOR
Intervention: R1 resection with limited lymphadenectomy
Number of subjects: 473
Study: 2256758

Group type: EXPERIMENTAL
Intervention: Ambulation starting on postoperative day 1 (group A)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Ambulation (group A)
Number of subjects: 34
Study: 6770409

Group type: EXPERIMENTAL
Intervention: Oral Contraceptives (OC)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Neogynon (a type of Oral Contraceptive)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Loop (Intrauterine Contraception)
Number of subjects: 35
Study: 31517847

Group type: EXPERIMENTAL
Intervention: Weekly cisplatin (WC)
Number of subjects: 0
Study: 28166848

Group type: EXPERIMENTAL
Intervention: Metacognitive Training (MCT)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Psycho-educational group
Number of subjects: 126
Study: 25877963

Group type: EXPERIMENTAL
Intervention: efavirenz 400 mg
Number of subjects: 636

Group type: COMPARATOR
Intervention: efavirenz 600 mg
Number of subjects: 636
Study: 23646839

Group type: EXPERIMENTAL
Intervention: Risk feedback intervention
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Self-affirmation manipulation
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Risk feedback intervention + Self-affirmation manipulation
Number of subjects: 292
Study: 20615930

Group type: EXPERIMENTAL
Intervention: Topiramate (up to 200 mg/day)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 43
Study: 19505589

Group type: EXPERIMENTAL
Intervention: Antiretroviral DOT (directly observed therapy)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 77
Study: 17998682

Group type: EXPERIMENTAL
Intervention: Radical radiotherapy
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Surgical excision of metastasis
Number of subjects: 1
Study: 15070666

Group type: EXPERIMENTAL
Intervention: Imatinib treatment
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 66
Study: 11334204

Group type: EXPERIMENTAL
Intervention: Short-term leukocyte filtration during reperfusion by release of the aortic crossclamp
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three different filtration concepts
Number of subjects: 0
Study: 9783600

Group type: EXPERIMENTAL
Intervention: Presacral drainage
Number of subjects: 48

Group type: COMPARATOR
Intervention: No drainage
Number of subjects: 48
Study: 7837397

Group type: EXPERIMENTAL
Intervention: Ulinastatin (600,000 units intravenously before CPB and before declamping of aorta)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ulinastatin (300,000 units added in the priming solution)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no ulinastatin)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 36
Study: 2452940

Group type: EXPERIMENTAL
Intervention: Antithyroid drugs started within 8 days after 131I
Number of subjects: 206

Group type: COMPARATOR
Intervention: Radioactive iodine (131I) alone
Number of subjects: 206
Study: 28918083

Group type: EXPERIMENTAL
Intervention: 0.1% fluorometholone (FML)
Number of subjects: 41

Group type: COMPARATOR
Intervention: polyvinyl alcohol (PA)
Number of subjects: 41
Study: 26936270

Group type: EXPERIMENTAL
Intervention: Goal attainment scaling rehabilitation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care rehabilitation
Number of subjects: 120
Study: 25546524

Group type: EXPERIMENTAL
Intervention: Epidural analgesia with low-dose bupivacaine and fentanyl
Number of subjects: 100

Group type: COMPARATOR
Intervention: No epidural analgesia
Number of subjects: 100
Study: 23024014

Group type: EXPERIMENTAL
Intervention: Weekly alcohol intake (10 units/week increase)
Number of subjects: 12700
Study: 20394042

Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: AKI
Number of subjects: 94

Group type: COMPARATOR
Intervention: No AKI
Number of subjects: 94
Study: 18477075

Group type: EXPERIMENTAL
Intervention: Fluid resuscitation guided by hourly urine output (HUO Group, n=12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fluid resuscitation guided by intrathoracic blood volume index (ITBVI Group, n=12)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups (HUO and ITBVI)
Number of subjects: 24
Study: 15909462

Group type: EXPERIMENTAL
Intervention: Vaginal ring with low dose progesterone (1.8 g)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Vaginal ring with high dose progesterone (3.6 g)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Vaginal ring (both doses)
Number of subjects: 29
Study: 12913766

Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 321

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 321
Study: 10594396

Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg o.d.)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Ranitidine (300 mg b.d.)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Lansoprazole (30 mg o.d.) and Ranitidine (300 mg b.d.)
Number of subjects: 133
Study: 8591120

Group type: EXPERIMENTAL
Intervention: Higher levels of dialysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urea kinetic modeling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newer membranes and higher levels of dialysis
Number of subjects: 0
Study: 1719288

Group type: EXPERIMENTAL
Intervention: Oral bisoprolol (20 mg) at rest
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oral bisoprolol (20 mg) with iterative stress tests
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo during exercise tests
Number of subjects: 8
Study: 84441

Group type: EXPERIMENTAL
Intervention: DTIC alone or in combination with other cytotoxic agents (Oncovin, Bleomycin, Adriblastin)
Number of subjects: 24
Study: 30756406

Group type: EXPERIMENTAL
Intervention: Intervention aimed at improving parent-school cooperation
Number of subjects: 2746

Group type: COMPARATOR
Intervention: Control group (14 control schools)
Number of subjects: 2746

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 2746
Study: 31173898

Group type: EXPERIMENTAL
Intervention: Decidua stromal cells (DSCs) infused at a median dose of 1.2 (range, 0.9 to 2.9) × 10^6 cells/kg body weight, median of 2 doses given 1 week apart.
Number of subjects: 21
Study: 30353893

Group type: EXPERIMENTAL
Intervention: Zinc oxide eugenol
Number of subjects: 2

Group type: COMPARATOR
Intervention: Alveogyl
Number of subjects: 2
Study: 25381202

Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 24517061

Group type: EXPERIMENTAL
Intervention: Warming Shen, enhancing Yang, invigorating qi, and nourishing blood method (WSEYIQNBM) combined artificial cycle therapy
Number of subjects: 96

Group type: COMPARATOR
Intervention: Western medicine artificial cycle therapy
Number of subjects: 96
Study: 21942916

Group type: EXPERIMENTAL
Intervention: C1‐INH NF concentrate 1000 U
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C1‐INH NF concentrate 1000 U (pre-procedural use)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C1‐INH NF concentrate 1000 U (routine prevention)
Number of subjects: 0
Study: 19288321

Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 50
Study: 18064333

Group type: EXPERIMENTAL
Intervention: G-CSF-mobilized peripheral blood mononuclear cells (M-PBMNC)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Bone marrow-mononuclear cells (BM-MNC)
Number of subjects: 150
Study: 15234477

Group type: EXPERIMENTAL
Intervention: Unexpected impacts at 15.4 m/s2
Number of subjects: 10

Group type: COMPARATOR
Intervention: Expected impacts at 15.4 m/s2
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Unexpected impacts
Number of subjects: 10
Study: 11528491

Group type: EXPERIMENTAL
Intervention: Liquid nutritional rehabilitation food
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Solid nutritional rehabilitation food
Number of subjects: 8

Group type: COMPARATOR
Intervention: Comparison of solid vs liquid
Number of subjects: 8
Study: 10189849

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy screening
Number of subjects: 3000
Study: 7917743

Group type: EXPERIMENTAL
Intervention: Sevoflurane anaesthesia (mean dose 10.6 MAC-h)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Isoflurane anaesthesia (mean dose 8.5 MAC-h)
Number of subjects: 21
Study: 3253122

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia
Number of subjects: 55

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both types of anaesthesia
Number of subjects: 55
Study: 31707767

Group type: EXPERIMENTAL
Intervention: Geriatric Nutritional Risk Index (GNRI) > 98 (no risk)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Geriatric Nutritional Risk Index (GNRI) 92-98 (low risk)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Geriatric Nutritional Risk Index (GNRI) < 92 (moderate/major risk)
Number of subjects: 352
Study: 29643029

Group type: EXPERIMENTAL
Intervention: FOS (fructo-oligosaccharides) for 5 days
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: GOS (galacto-oligosaccharides) for 9 days
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Prediction model based on initial gut microbiota data
Number of subjects: 35
Study: 28109731

Group type: EXPERIMENTAL
Intervention: Food condition (participants who had recently eaten)
Number of subjects: 173

Group type: COMPARATOR
Intervention: No food condition (participants who had not recently eaten)
Number of subjects: 173
Study: 25142278

Group type: EXPERIMENTAL
Intervention: 12 week gym and home walking exercise programme (n=13)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy comparator group
Number of subjects: 30
Study: 23283590

Group type: EXPERIMENTAL
Intervention: Diffusion-weighted MRI (ADC values before radiochemotherapy)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Diffusion-weighted MRI (ΔADC)
Number of subjects: 59
Study: 21622083

Group type: EXPERIMENTAL
Intervention: Improved biomass stove (Patsari stove)
Number of subjects: 63
Study: 17443125

Group type: COMPARATOR
Intervention: 0 mg nicotine via nasal spray
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 1 mg nicotine via nasal spray
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 2 mg nicotine via nasal spray
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Nicotine (any dose)
Number of subjects: 28
Study: 17274039

Group type: EXPERIMENTAL
Intervention: Cabergoline (CAB) 2 or 3 mg daily for 30 weeks
Number of subjects: 361

Group type: COMPARATOR
Intervention: Levodopa 200 or 300 mg daily for 30 weeks
Number of subjects: 361

Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Cabergoline
Number of subjects: 361
Study: 15492340

Group type: EXPERIMENTAL
Intervention: Nurse care management (structured telephone surveillance and treatment for heart failure, coordination with primary care physicians)
Number of subjects: 462

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 462
Study: 11525777

Group type: EXPERIMENTAL
Intervention: etodolac (200 or 400 b.i.d.)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: meloxicam (7.5 or 15 q.d.)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: nimesulide (100 or 200 b.i.d.)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: nabumetone (500 or 1000 b.i.d.)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: naproxen (500 b.i.d.)
Number of subjects: 5
Study: 9632874

Group type: EXPERIMENTAL
Intervention: TAPP (group 1 = 52 cases)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: TAPP (group 1)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Open (group 2 = 56 cases)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: TAPP
Number of subjects: 108

Group type: COMPARATOR
Intervention: Open
Number of subjects: 108
Study: 8160609

Group type: EXPERIMENTAL
Intervention: Low-fat diet and daily physical exercise
Number of subjects: 104

Group type: COMPARATOR
Intervention: Usual care by private physician
Number of subjects: 104
Study: 3042053

Group type: EXPERIMENTAL
Intervention: CMF + tamoxifen (30 mg per day during 2 years)
Number of subjects: 326

Group type: COMPARATOR
Intervention: CMF (chemotherapy alone)
Number of subjects: 326
Study: 31490429

Group type: EXPERIMENTAL
Intervention: S + SA
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: E + SA
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: C + SA
Number of subjects: 27

Group type: COMPARATOR
Intervention: SA
Number of subjects: 27
Study: 31501112

Group type: COMPARATOR
Intervention: Standard GIST (n=30) delivered via outpatient sessions for 2.5 hours once per week for 12 weeks, plus one initial orientation session.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intensive GIST (n=30) participants admitted to an inpatient rehabilitation unit for 4 weeks (two times 3 days/week, two times 4 days/week) with full-day sessions each week.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Wait-list control group (WL) for participants receiving intensive GIST after WL.
Number of subjects: 60
Study: 27761942

Group type: EXPERIMENTAL
Intervention: Advanced carbohydrate counting using an automated bolus calculator (ABC group)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Advanced carbohydrate counting using mental calculations (MC group)
Number of subjects: 168
Study: 24408892

Group type: EXPERIMENTAL
Intervention: PEERS(®) treatment group (TG)
Number of subjects: 47
Study: 22018935

Group type: EXPERIMENTAL
Intervention: Intensive diet, physical activity, and meditation intervention
Number of subjects: 47

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Increased fruit and fiber intakes
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Increased saturated fatty acid intake
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Decreased or maintained saturated fatty acid intake
Number of subjects: 47
Study: 21938126

Group type: EXPERIMENTAL
Intervention: 5% imiquimod cream
Number of subjects: 100
Study: 17403126

Group type: COMPARATOR
Intervention: Metformin and twice daily biphasic 30/70 human insulin mixture (n = 27)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Metformin and bedtime NPH insulin (n = 26)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Metformin, bedtime NPH insulin and mealtime repaglinide (n = 25)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 82
Study: 15871642

Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg intravenously (n=37)
Number of subjects: 78

Group type: COMPARATOR
Intervention: prochlorperazine 10 mg intramuscularly (n=41)
Number of subjects: 78
Study: 12851985

Group type: EXPERIMENTAL
Intervention: Anti-TNF-alpha immunobiologics (e.g. etanercept, infliximab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Apoptosis-inducing treatments
Number of subjects: 0
Study: 9834301

Group type: EXPERIMENTAL
Intervention: High-dose cytarabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Autologous marrow transplantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Allogeneic marrow transplantation
Number of subjects: 0
Study: 8012440

Group type: EXPERIMENTAL
Intervention: Laminaria digitata tents
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cervical dilatation without Laminaria tents
Number of subjects: 30
Study: 2607127

Group type: EXPERIMENTAL
Intervention: Lofepramine (140 mg)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 30676482

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) for 3 months
Number of subjects: 194

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 194
Study: 28838362

Group type: EXPERIMENTAL
Intervention: AUC-based educational intervention
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 196
Study: 26272720

Group type: EXPERIMENTAL
Intervention: Ephedrine 10 mg iv at the time of CSE
Number of subjects: 596

Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 596
Study: 24030086

Group type: EXPERIMENTAL
Intervention: Torsional phacoemulsification
Number of subjects: 52

Group type: COMPARATOR
Intervention: Longitudinal phacoemulsification
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Preoperative CCT
Number of subjects: 52
Study: 21170794

Group type: EXPERIMENTAL
Intervention: Cold water immersion (10 min, 10°C)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Thermoneutral water immersion (10 min, 35°C)
Number of subjects: 20
Study: 18415103

Group type: EXPERIMENTAL
Intervention: AcrySof IQ IOL (22.4+/‐2.0 D)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: AcrySof IQ IOL
Number of subjects: 106

Group type: COMPARATOR
Intervention: AcrySof SA60AT
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Corneal asphericity (Q value)
Number of subjects: 106
Study: 17012454

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (80 units injected into pelvic floor muscles)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (saline injection)
Number of subjects: 60
Study: 14612479

Group type: EXPERIMENTAL
Intervention: Antidepressant medications and/or 6 to 8 sessions of psychotherapy (Problem‐Solving Treatment in Primary Care)
Number of subjects: 1801
Study: 11177604

Group type: EXPERIMENTAL
Intervention: Detection of isolated disseminated tumor cells in bone marrow (IDTBM) using monoclonal antibody A 45‐B/B3
Number of subjects: 293
Study: 8959119

Group type: EXPERIMENTAL
Intervention: EDC spirometer
Number of subjects: 10

Group type: COMPARATOR
Intervention: mini-Wright peak flow meter
Number of subjects: 10
Study: 1431257

Group type: COMPARATOR
Intervention: M15 (15 mg/kg)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: M25 (25 mg/kg)
Number of subjects: 199
Study: 3881630

Group type: EXPERIMENTAL
Intervention: Intratumoral immunotherapy with Corynebacterium parvum followed 2 weeks later by surgery and postoperative C parvum for 2 years
Number of subjects: 176

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Intratumoral C parvum
Number of subjects: 176
Study: 29908472

Group type: EXPERIMENTAL
Intervention: CBM Attention Dot‐Probe Training (DPT)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: CBM Approach‐Avoidance Training (AAT)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 139
Study: 27504918

Group type: EXPERIMENTAL
Intervention: Pessary treatment
Number of subjects: 162

Group type: COMPARATOR
Intervention: PFMT
Number of subjects: 162
Study: 25123333

Group type: EXPERIMENTAL
Intervention: Screen-detected lung cancers from positive CXR screens
Number of subjects: 77445

Group type: EXPERIMENTAL
Intervention: True interval lung cancers
Number of subjects: 77445
Study: 22816878

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol maintenance and reliever therapy (Symbicort SMART™, Turbuhaler®) 160/4.5 μg twice daily plus as needed
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional fixed-dose treatment (ICS/LABA plus SABA or formoterol)
Number of subjects: 0
Study: 20423357

Group type: EXPERIMENTAL
Intervention: Psychological support group with respiratory-sinus-arrhythmia biofeedback training (n = 106)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control group with standard care (n = 106)
Number of subjects: 212
Study: 18662913

Group type: EXPERIMENTAL
Intervention: 0.05% ciclosporin and dexamethasone 0.1%
Number of subjects: 47

Group type: COMPARATOR
Intervention: Dexamethasone only
Number of subjects: 47
Study: 15957600

Group type: EXPERIMENTAL
Intervention: Two-stage algorithm for mammogram registration
Number of subjects: 0
Study: 14534844

Group type: EXPERIMENTAL
Intervention: VAC dressings
Number of subjects: 6

Group type: COMPARATOR
Intervention: Moist gauze dressings
Number of subjects: 6
Study: 10836651

Group type: EXPERIMENTAL
Intervention: Daclizumab (1 mg/kg for five doses given every 2 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (mycophenolate mofetil, prednisone, and a calcineurin inhibitor)
Number of subjects: 36
Study: 8857000

Group type: EXPERIMENTAL
Intervention: Information search about each alternative
Number of subjects: 0

Group type: COMPARATOR
Intervention: Directly available information to another group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Information search and sequence of responding for three errands
Number of subjects: 0
Study: 1281903

Group type: EXPERIMENTAL
Intervention: Self-expanding metal stent
Number of subjects: 105

Group type: COMPARATOR
Intervention: Polyethylene stent
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness
Number of subjects: 105
Study: 6392050

Group type: EXPERIMENTAL
Intervention: 8 mg molsidomine sustained-release
Number of subjects: 11

Group type: COMPARATOR
Intervention: 2 mg molsidomine
Number of subjects: 11